Project Grant R01MH143145
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded J. David Gladstone Institutes a Project Grant totaling $2,177,199 under the Mental Health Research Grants program (CFDA 93.242), effective September 1, 2025, through August 31, 2027. This two-phase, milestone-driven research initiative aims to develop and validate a novel humanized microglia-neural cell (HUMGN) mouse model that incorporates human microglia, neurons, and astrocytes differentiated from induced...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Alabama at Birmingham $1.81M under the Mental Health Research Grants program (CFDA 93.242) on June 5, 2026, with completion targeted for June 4, 2028. This Project Grant supports the development of next-generation preclinical models of neuroHIV (HIV-related central nervous system dysfunction) that incorporate multiple human cell types and an intact blood-brain barrier in the context of...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a $1.1 million Project Grant (CFDA 93.242: Mental Health Research Grants) effective May 1, 2026 through January 31, 2031 to conduct research investigating the effects of broadly neutralizing antibody (BnAb) treatment on neuroinflammation and central nervous system (CNS) persistence in simian immunodeficiency virus (SIV)-infected antiretroviral therapy (ART)-suppressed macaques. The...
- Federal Grant Award Summary Yale University received a $491,700 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded September 3, 2025, with a completion date of September 2, 2027. The project investigates the role of cerebrospinal fluid (CSF) memory B cells in neuropathogenesis among people with HIV (PWH) on antiretroviral therapy (ART). The research addresses a critical knowledge gap by examining how B cells...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded Icahn School of Medicine at Mount Sinai a $3.6M Project Grant under the Mental Health Research Grants program (CFDA 93.242) on September 22, 2025, with a completion date of September 21, 2029. This research project, titled "Targeting the NLRP3 Inflammasome to Mitigate Neuroinflammation and HIV Persistence in the CNS: Mechanisms and Therapeutic Strategies," investigates the role of the NLRP3...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded $837,097 to The University of Texas Southwestern Medical Center on September 22, 2025, under the Mental Health Research Grants program (CFDA 93.242) to conduct a five-year imaging study examining microglia proliferation and its relationship to cognitive control deficits in virally-suppressed people with human immunodeficiency virus (VS+PWH). The project, extending through May 31, 2030, utilizes positron...
- Federal Project Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $431,750 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) awarded on May 15, 2026, with a completion date of May 14, 2028. The grant supports basic research investigating the molecular mechanisms underlying human immunodeficiency virus (HIV) latency and persistence in the central nervous system...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a $149,190 Project Grant effective August 2, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct research identifying intervention opportunities for cognitive impairment among persons aging with HIV. The research will leverage two established cohort studies—the Multicenter AIDS Cohort Study (MACS) and the Johns Hopkins HIV Clinical Cohort (JHHCC)—to...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $759,816 Project Grant to The Regents of the University of California, Berkeley, effective May 1, 2026, through January 31, 2031, under the Mental Health Research Grants program (CFDA 93.242). This award supports the development and application of targeted machine learning estimators (TMEs) to address critical methodological gaps in cluster randomized trials (CRTs) evaluating HIV prevention...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Columbia University's Health Sciences Division a $751,490 Project Grant (CFDA 93.242, Mental Health Research Grants) effective April 1, 2026, through March 31, 2029, to develop and evaluate a comprehensive resource package for implementing clinical decision support (CDS) systems in HIV clinics nationwide. The project addresses implementation barriers to long-acting injectable (LAI) pre-exposure prophylaxis and...
The National Institute of Mental Health (NIMH) awarded a $787,498 Project Grant to the University of California, Los Angeles (UCLA) effective July 1, 2026, through March 31, 2031, under the Mental Health Research Grants program (CFDA 93.242). The research initiative, titled "Characterization of HIV Persistence and Neuroinflammation in the CNS Reservoir In Vivo," investigates the mechanisms by which human immunodeficiency virus (HIV) persists in central nervous system (CNS) reservoirs despite effective combination antiretroviral therapy (ART). The project addresses a critical gap in understanding how infiltrating T cells contribute to viral persistence and chronic neuroinflammation in the CNS, conditions that hamper clinical outcomes in people with HIV. UCLA will employ an integrated research approach utilizing barcoded HIV tracking systems, spatial transcriptomics, single-cell RNA sequencing, and integration site analysis within a novel humanized mouse model to characterize viral reservoirs and define T cell-mediated mechanisms of persistence and inflammation in the CNS. This research builds upon preliminary findings demonstrating robust infection establishment in peripheral and CNS tissues with upregulated Type I interferon signaling, and prior non-human primate studies showing that HIV-specific chimeric antigen receptor (CAR) T cells derived from genetically modified hematopoietic stem/progenitor cells (HSPCs) can traffic to the CNS and reduce viral burden. The findings are intended to optimize CNS reservoir-targeted therapies and inform strategies for delivering therapeutic antiviral T cells to address HIV-associated neuropathogenesis.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $787.5k | 6/25/26 |